Medical uses:

Kevzara is an injectable prescription medication that acts as an interleukin-6 (IL-6) receptor antagonist. It is used to treat adults with moderately to severely active rheumatoid arthritis (RA) who have not responded adequately or are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).

Recommended Dosage: Kevzara can be used alone or in combination with methotrexate (MTX) or other conventional DMARDs. The standard dosage is 200 mg every two weeks, administered via subcutaneous injection. If necessary, the dosage can be reduced to 150 mg every two weeks to manage thrombocytopenia, neutropenia, or elevated liver enzymes.

Initiation Guidelines: Kevzara should not be started in patients with a platelet count below 150,000 per mm³, an absolute neutrophil count (ANC) below 2000 per mm³, or ALT/AST levels greater than 1.5 times the upper limit of normal (ULN).

Pre-Treatment Testing: Patients should be tested for latent tuberculosis (TB) before starting Kevzara. If the test is positive, consider treating TB before beginning Kevzara therapy.

Drug Interactions: Avoid using Kevzara with biological DMARDs due to the increased risk of immunosuppression and infection. The safety of using Kevzara with other biological DMARDs, such as IL-1R antagonists, TNF antagonists, anti-CD20 monoclonal antibodies, and selective co-stimulation modulators, has not been established. Do not use Kevzara in patients with active infections.

Warnings & Precautions:

Severe and potentially fatal infections caused by bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens can occur in patients receiving immunosuppressive agents like sarilumab for rheumatoid arthritis (RA). The most common serious infections with this drug include pneumonia and cellulitis.

Precautions:

• Active Infections: Avoid using Sarilumab in patients with active infections, including localized ones.
• Risk Assessment: Consider the risks and benefits before starting therapy in patients with chronic or recurrent infections, known opportunistic infections, exposure to TB, or those who have lived in or traveled to areas with endemic TB or mycoses.
• Monitoring: Closely monitor patients for signs and symptoms of infection during treatment, as acute inflammation signs may be suppressed. Discontinue Kevzara if a severe or opportunistic infection develops.
• Diagnostic Testing: Perform thorough diagnostic testing for immunocompromised patients who develop new infections during therapy. Initiate appropriate antimicrobial treatment and monitor the patient closely.

Tuberculosis (TB) Screening:

• Assess patients for TB risk factors and test for latent infection before starting Sarilumab. Treat latent TB with standard antimycobacterial therapy before initiating Sarilumab. Monitor patients for TB symptoms, even those who tested negative for latent TB before starting therapy.

Blood Count Monitoring:

• Neutrophils: Sarilumab treatment is associated with a higher incidence of reduced absolute neutrophil count (ANC), including neutropenia. Evaluate neutrophil count before starting treatment and monitor 4-8 weeks after initiation and every three months thereafter.
• Platelets: Sarilumab can reduce platelet counts. Evaluate platelet count before starting therapy and monitor 4-8 weeks after initiation and every three months thereafter.

Liver Function Monitoring:

• Transaminase Levels: Sarilumab is associated with higher transaminase levels. Evaluate ALT and AST levels before starting therapy and monitor 4-8 weeks after initiation and every three months thereafter. Consider other liver functions, such as bilirubin, if needed.

Lipid Monitoring:

• Lipid Parameters: Sarilumab can increase lipid levels, including LDL/HDL cholesterol and triglycerides. Evaluate lipid parameters 4-8 weeks after starting therapy and then every six months. Manage hyperlipidemia according to clinical guidelines.

Gastrointestinal (GI) Risks:

• GI Perforation: GI perforation, primarily as a complication of diverticulitis, may occur. The risk is higher with concurrent diverticulitis or the use of NSAIDs or corticosteroids. Immediately assess new onset abdominal symptoms.

Hypersensitivity Reactions:

• Reactions: Hypersensitivity reactions, including injection site rash, rash, and urticaria, may occur. Seek prompt medical attention for any signs of hypersensitivity. Discontinue treatment in case of anaphylaxis or other severe reactions. Do not use Sarilumab in patients with known hypersensitivity to the drug.

Hepatic Impairment:

• Liver Disease: Sarilumab is not recommended for patients with active hepatic disease or impairment due to the risk of transaminase elevations.

Vaccinations:

• Live Vaccines: Avoid using live vaccines during Sarilumab therapy due to the increased risk of infections. Follow current vaccination guidelines for immunosuppressive agents regarding the timing between live vaccinations and the initiation of Sarilumab therapy.

Documentation & Availability :

Documents  required to import  KEVZARA® to India? 

 KEVZARA® (sarilumab) injection can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:

1. 2 ID proofs along with PAN card details along with attested scanned copies
2. Valid doctor prescription scanned copy
3. Doctor’s MCI number
4. Doctor’s mobile number
5. Patients diagnostic reports

How is the order confirmed? 

The order will be confirmed only after the receipt of:

1. The above-mentioned documents and drug availability.
2. Import permit if applicable.

Sourcing & Delivery:

The Rx4U team has extensive experience in sourcing   KEVZARA® (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.

 FAQ:

What is the generic name for the trade name drug Kevzara®?

The generic name for Kevzara® is Sarilumab.

Who manufactures Kevzara®?

Kevzara® is manufactured by Sanofi and Regeneron Pharmaceuticals, Inc.

Is Kevzara® approved by the FDA?

Yes, Kevzara® was approved by the FDA on May 22, 2017.

Where can I get Kevzara® at the best price in India?

For the best price on Kevzara® in India, contact Rx4u team.

What dosage form is Kevzara® available in?

Kevzara® is available as a 150 mg/1.14 mL or 200 mg/1.14 mL solution in a single-dose pre-filled syringe for subcutaneous injection.

What are the most common side effects of Kevzara®?

The most common side effects of Kevzara® include upper respiratory infections, injection site erythema, increased ALT, neutropenia, and urinary tract infections.

What are the storage conditions for Kevzara®?

Store Kevzara® in its original carton at 36-46°F (2-8°C) to protect it from light. Do not freeze or shake the medication. If needed, Kevzara® can be stored at room temperature up to 77°F (25°C) for up to 2 weeks. After removal from the refrigerator, use within 2 weeks or discard.

Is it safe to buy Kevzara® online from India?

Yes, you can safely purchase Kevzara® online in India through https://rx4u.in/.

*Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.